ACP
ANAB icon

Acuta Capital Partners’s AnaptysBio ANAB Stock Holding History

Acuta Capital Partners’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-165,690
Closed -$3.96M – 66
2017
Q2 		$3.96M Hold
165,690
– – 1.11% 22
2017
Q1 		$4.14M Buy
+165,690
New +$3.86M 0.98% 29

Other funds holding ANAB

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Acuta Capital Partners's ANAB Position: Q3 2017 in Review

Acuta Capital Partners sold out of AnaptysBio (ANAB) in Q3 2017, closing a stake of 165,690 shares — an estimated $3.96M sold.

Acuta Capital Partners first reported a position in ANAB in Q1 2017 and held it in 2 quarters. The position peaked at $4.14M in Q1 2017. 71 funds tracked by Wall St. Rank hold ANAB as of Q3 2017.

  • Acuta Capital Partners reported no remaining AnaptysBio position as of Q3 2017 after selling out during the quarter.
  • Acuta Capital Partners sold 165,690 AnaptysBio shares in Q3 2017, an estimated $3.96M.
  • Acuta Capital Partners first reported a position in AnaptysBio in Q1 2017 and held it in 2 quarters.
  • Acuta Capital Partners's AnaptysBio position peaked at $4.14M in Q1 2017.
  • 71 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2017.

Based on Acuta Capital Partners's 13F filing for Q3 2017, filed 14 Nov 2017.